giroctocogene fitelparvovec, fidanacogene elaparvovec
C0371017
Phase 3 small_molecule active
Quick answer
giroctocogene fitelparvovec, fidanacogene elaparvovec for hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%) is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active